Advanced search
Publication Cover
Current Medical Research and Opinion Volume 23, 2007 - Issue 9
Submit an article Journal homepage
45
Views
8
CrossRef citations to date
0
Altmetric
Original Article

A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer

Alain J. Gelibter Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, ItalyCorrespondence[email protected]
,
Teresa Gamucci Division of Medical Oncology, SS Trinità Hospital, Sora, Italy
,
Camillo F. Pollera Division of Medical Oncology, Belcolle Hospital, Viterbo, Italy
,
Francesco Di Costanzo Division of Medical Oncology, Azienda Ospedale Careggi, Florence, Italy
,
Carmen Nuzzo Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
,
Angela Gabriele Division of Medical Oncology, SS Trinità Hospital, Sora, Italy
,
Carlo Signorelli Division of Medical Oncology, Belcolle Hospital, Viterbo, Italy
,
Silvia Gasperoni Division of Medical Oncology, Azienda Ospedale Careggi, Florence, Italy
,
Virginia Ferraresi Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
,
Diana Giannarelli Statistic Unit, Regina Elena National Cancer Institute, Rome, Italy
,
Francesco Cognetti Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
&
Massimo Zeuli Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
 show all
Pages 2117-2123 | Accepted 28 Jun 2007, Published online: 24 Jul 2007

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Hafiz A. Makeen, Syam Mohan, Mohamed Ahmed Al-Kasim, Ibraheem M. Attafi, Rayan A. Ahmed, Nabeel Kashan Syed, Muhammad Hadi Sultan, Mohammed Al-Bratty, Hassan A. Alhazmi, Mohammed M. Safhi, Raisuddin Ali & M. Intakhab Alam. (2020) Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro. Drug Delivery 27:1, pages 622-631.
Read now

Articles from other publishers (7)

Brigette B. Y. Ma, Stephen L. Chan, Wing M. Ho, Wilson Lau, Frankie Mo, Edwin P. Hui, Charles Chan, Annette Poon, Rasalkar D. Dattatray, S. C. Cesar Wong, Ka F. To, Ann D. King, Anil Ahuja & Anthony T. C. Chan. (2013) Intermittent versus continuous erlotinib with concomitant modified “XELOX” (q3W) in first-line treatment of metastatic colorectal cancer. Cancer 119:23, pages 4145-4153.
Crossref
Andrew M. Bellizzi. (2013) Contributions of molecular analysis to the diagnosis and treatment of gastrointestinal neoplasms. Seminars in Diagnostic Pathology 30:4, pages 329-361.
Crossref
Francesco Torino, Roberta Sarmiento & Giampietro Gasparini. (2013) The contribution of targeted therapy to the neoadjuvant chemoradiation of rectal cancer. Critical Reviews in Oncology/Hematology 87:3, pages 283-305.
Crossref
Amartej Merla & Sanjay Goel. (2012) Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review. Chemotherapy Research and Practice 2012, pages 1-11.
Crossref
Wells A. Messersmith, Antonio Jimeno, Heather Jacene, Ming Zhao, Piotr Kulesza, Daniel A. Laheru, Yasmin Kahn, Alexander Spira, Janet Dancey, Christine Iacobuzio-Donahue, Ross C. Donehower, Michael Carducci, Michelle A. Rudek & Manuel Hidalgo. (2010) Phase I Trial of Oxaliplatin, Infusional 5-Fluorouracil, and Leucovorin (FOLFOX4) With Erlotinib and Bevacizumab in Colorectal Cancer. Clinical Colorectal Cancer 9:5, pages 297-304.
Crossref
I Chau & D Cunningham. (2009) Treatment in advanced colorectal cancer: what, when and how?. British Journal of Cancer 100:11, pages 1704-1719.
Crossref
Rachel Wong & David Cunningham. (2008) What is the impact of biologicals in colorectal cancer?. Targeted Oncology 3:2, pages 59-69.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.